AbbVie's (ABBV) Atrasentan Receives Orphan Drug Designation
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
AbbVie (NYSE: ABBV) Atrasentan for treatment of pediatric nephrotic syndrome was granted an FDA Orphan Drug Designation.
|Orphan Designation:||Treatment of pediatric nephrotic syndrome|
|Orphan Designation Status:||Designated|
|FDA Orphan Approval Status:||Not FDA Approved for Orphan Indication|
|Marketing Approval Date:||N/A|
|Approved Labeled Indication:|
|Exclusivity End Date:||N/A|
1 North Waukegan Road
North Chicago, Illinois 60044
The sponsor address listed is the last reported by the sponsor to OOPD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Blood Therapeutics (GBT) Reaches Agreement with FDA on Design of Phase 3 GBT440 Trial in SCD
- Vail Resorts (MTN) Names New Board Member
- Windtree Therapeutics (WINT) Releases Data from Lung Deposition Study Conducted in Non-Human Primates
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!